Memando

Memantine Hydrochloride, the active ingredient in Memando, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Memando as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across EU and global markets. The company leverages validated manufacturing processes and reliable logistics to meet the needs of healthcare providers.

Memando, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease and related cognitive decline.

Alzheimer’s disease (mild to moderate): provides modest improvement in cognition and memory. Alzheimer’s disease (moderate to severe): helps maintain functional abilities and daily activities. Behavioral symptoms of Alzheimer’s disease: may reduce agitation and improve overall patient behavior.

Memando may be associated with a range of adverse reactions, varying from common to serious.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Hypertension

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (e.g., rash, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic dysfunction (elevated liver enzymes)

When prescribing Memando, clinicians should consider several safety precautions to minimize risk.

Renal impairment: adjust dose or monitor renal function closely. History of seizures: monitor for increased seizure activity. Cardiovascular disease: observe blood pressure and heart rate. Concurrent use with other NMDA antagonists: avoid combined therapy. Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Memando can interact with other medicines, necessitating careful review of a patient’s medication regimen.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity and confusion. - Other NMDA antagonists (e.g., ketamine): additive central nervous system effects. - Anticholinesterase inhibitors (e.g., donepezil): may reduce therapeutic benefit. - High‑dose diuretics: can raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: potential additive blood pressure lowering. - Anticholinergic drugs: may exacerbate cognitive side effects. - CYP2D6 inhibitors (e.g., fluoxetine): may modestly increase memantine levels.